HIF-1 alpha gene therapy - Sanofi Genzyme

Drug Profile

HIF-1 alpha gene therapy - Sanofi Genzyme

Alternative Names: Ad2/HIF-1 alpha; Ad2/HIF-1a; Ad2/HIF-1α/VP16; Cardiovascular disease gene therapy - Sanofi Genzyme

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Genzyme Corporation
  • Class Gene therapies; Peripheral vasodilators
  • Mechanism of Action Angiogenesis inducing agents; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Intermittent claudication; Peripheral arterial disorders
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 31 Mar 2012 No development reported - Phase-II for Intermittent claudication in European Union (IM)
  • 31 Mar 2012 No development reported - Phase-II for Intermittent claudication in USA (IM)
  • 31 Mar 2012 No development reported - Phase-II for Peripheral arterial disorders in European Union (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top